Study can orient use of melatonin in the treatment of breast cancer

December 08, 2020

A Brazilian study published in the Journal of Pineal Research describes a group of genes potentially regulated by the hormone melatonin in some types of cancer, especially breast cancer. According to the authors, the results can be used to guide future personalized therapies for the disease.

“Certain types of tumor appear to correlate directly with the amount of melatonin produced by cells. It’s essential to understand how the hormone influences molecular signaling at the genetic level as a guideline for personalized therapies based on melatonin,” Luiz Gustavo Chuffa, a professor at São Paulo State University’s Botucatu Institute of Biosciences (IBB-UNESP), told Agência FAPESP.

The study was supported by FAPESP and conducted in collaboration with researchers at the University of North Paraná (UENP) and São José do Rio Preto Medical School (FAMERP) in Brazil and the University of Texas Health Science Center at San Antonio in the United States.

Known as the “sleep hormone” because its functions include regulating the sleep-wake cycle, melatonin has been shown to have anti-tumor properties in laboratory trials. Evidence presented in the scientific literature suggests that low levels of melatonin are associated with a heightened risk of cancer. A possible explanation is that the hormone contributes to the modulation of gene expression and may intensify the activity of tumor suppressor genes, for example.

“Most tumor cells have low levels of melatonin, but laboratory trials have shown that treatment with the hormone increases tumor cell death and reduces tumor cell proliferation, both of which are important to avoid progression of the cancer and metastasis,” Chuffa said. “Ongoing clinical trials are evaluating the use of melatonin to treat cancer. Specific therapies for the different subtypes of breast cancer already exist, and some patients will probably respond well to alternative treatments based on melatonin, while others may not.”

In search of target genes

To identify molecular markers that serve as guides for cancer treatment, the researchers first conducted a study based on meta-analysis to find out how melatonin regulates microRNA expression in breast, head and neck, liver, stomach, prostate, central nervous system, and colorectal cancer.

Meta-analysis entails a systematic review of the literature using statistical methods to integrate the results of published research on the same subject. MicroRNAs are small RNA molecules that do not encode proteins but perform a regulatory function in the genome, controlling gene expression and hence several cellular processes.

“In this first stage, we found 14 quite recent studies that associated melatonin with altered microRNA expression. For the seven cancers on which we focused, we found 46 microRNAs with altered expression,” Chuffa said.

Next, the researchers used bioinformatics to identify pathways associated with the hormone’s action on tumor cells, basing their analysis on the association between these microRNAs and their regulatory targets. Regulatory and molecular networks were generated and analyzed in collaboration with researchers Robson Francisco Carvalho, Luis Antonio Justulin, and Sarah Santiloni.

“When we cross-referenced the information with The Cancer Genome Atlas [TCGA], a public database, we identified the target genes for these 46 microRNAs with altered expression,” Chuffa said.

As a result, they were able to understand how melatonin works in several cellular signaling pathways. “These genes targeted by melatonin relate to important biological processes in cancer, such as cell cycle regulation, cell death, and cell migration and senescence,” he explained. “Melatonin appears to act more strongly on breast, oral, and stomach cancer. Prostate and colorectal tumors, as well as glioblastoma, showed few changes induced by the microRNAs concerned.”

Breast cancer was associated with the most genes and microRNAs in this first stage of the study, so the researchers compared the target genes for the microRNAs concerned with the data obtained by RNA-seq analysis of breast tumors in mice treated with melatonin.

RNA-seq uses next-generation sequencing technology to study the expression of several genes at the same time and hence to obtain the entire transcriptome, i.e. the complete set of RNA molecules expressed in a tissue.

These analyses were performed in partnership with FAMERP researchers Débora Aparecida Pires de Campos Zuccari and Bruna Victorasso Jardim-Perassi.

“In the animals treated with 40 milligrams of melatonin, there was an enrichment of signaling pathways related to the immune system and apoptosis, and a reduction of pathways associated with tumor aggressiveness and metastasis,” Chuffa said.

The group also investigated certain proteins (transcription factors and kinases) that are active in such processes as transcription and the cellular cycle. “The goal of this part of the study was to find common targets in cellular processes and the breast cancer public database,” he said.

According to Chuffa, genes regulated by melatonin in breast cancer are potential targets for the treatment of the disease. “Melatonin is a multitasking molecule and acts on various cellular substrates, so we’re now taking the study deeper to find out how the hormone influences microRNA expression and hence the regulation of the cellular mechanisms identified,” he said.
-end-
About São Paulo Research Foundation (FAPESP)

The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at http://www.fapesp.br/en and visit FAPESP news agency at http://www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.

Fundação de Amparo à Pesquisa do Estado de São Paulo

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.